UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders

Annals of the New York Academy of Sciences, 2010-02, Vol.1187 (1), p.4-34

2010

Volltextzugriff (PDF)

Selective antagonism at dopamine D3 receptors as a target for drug addiction pharmacotherapy: a review of preclinical evidence

CNS & neurological disorders drug targets, 2008-11, Vol.7 (5), p.410-421

Heidbreder, Christian

2008

Volltextzugriff (PDF)

The medial prefrontal cortex in the rat: evidence for a dorso-ventral distinction based upon functional and anatomical characteristics

Neuroscience and Biobehavioral Reviews, 2003-10, Vol.27 (6), p.555-579

2003

Volltextzugriff (PDF)

Synthetic opioids have disrupted conventional wisdom for treating opioid overdose

Drug and alcohol dependence reports, 2024-09, Vol.12, p.100268, Article 100268

2024

Volltextzugriff (PDF)

Editorial: Discovery, development and implementation of improved options for treating opioid overdose in the synthetic opioid era

Frontiers in psychiatry, 2024-07, Vol.15, p.1443304

2024

Volltextzugriff (PDF)

Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder

Frontiers in pharmacology, 2022-11, Vol.13, p.1052113-1052113

2022

Volltextzugriff (PDF)

History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder

Drug and alcohol dependence reports, 2023-03, Vol.6, p.100133, Article 100133

2023

Volltextzugriff (PDF)

The introduction of a novel formulation of buprenorphine into organized health systems

Drug and alcohol dependence reports, 2022-09, Vol.4, p.100090-100090, Article 100090

2022

Volltextzugriff (PDF)

SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models

European journal of pharmacology, 2006-12, Vol.553 (1-3), p.109-119

2006

Volltextzugriff (PDF)

High-performance liquid chromatography/tandem mass spectrometric assay for the simultaneous measurement of dopamine, norepinephrine, 5-hydroxytryptamine and cocaine in biological samples

Journal of neuroscience methods, 2004-09, Vol.138 (1), p.123-132

2004

Volltextzugriff (PDF)

Selective dopamine D3 receptor antagonism by SB-277011A attenuates cocaine reinforcement as assessed by progressive-ratio and variable-cost-variable-payoff fixed-ratio cocaine self-administration in rats

The European journal of neuroscience, 2005-06, Vol.21 (12), p.3427-3438

2005

Volltextzugriff (PDF)

Antagonism at metabotropic glutamate 5 receptors inhibits nicotine- and cocaine-taking behaviours and prevents nicotine-triggered relapse to nicotine-seeking

European journal of pharmacology, 2004-09, Vol.499 (1), p.121-133

2004

Volltextzugriff (PDF)

The effects of lamotrigine on alcohol seeking and relapse

Neuropharmacology, 2007-12, Vol.53 (8), p.951-957

2007

Volltextzugriff (PDF)

Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex

Neuroscience letters, 2005-10, Vol.387 (3), p.157-161

2005

Volltextzugriff (PDF)

Selective antagonism at dopamine D3 receptors attenuates cocaine-seeking behaviour in the rat

The international journal of neuropsychopharmacology, 2007-04, Vol.10 (2), p.167-181

2007

Volltextzugriff (PDF)

Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior

Neuropsychopharmacology (New York, N.Y.), 2003-07, Vol.28 (7), p.1272-1280

2003

Volltextzugriff (PDF)

The selective dopamine D3 receptor antagonist SB-277011A attenuates drug- or food-deprivation reactivation of expression of conditioned place preference for cocaine in male sprague-dawley rats

Synapse (New York, N.Y.), 2015-06, Vol.69 (6), p.336-345

2015

Volltextzugriff (PDF)

Rationale in support of the use of selective dopamine D3 receptor antagonists for the pharmacotherapeutic management of substance use disorders

Naunyn-Schmiedeberg's archives of pharmacology, 2013-02, Vol.386 (2), p.167-176

Heidbreder, Christian

2013

Volltextzugriff (PDF)

Orexin-1 receptor antagonist SB-334867 reduces the acquisition and expression of cocaine-conditioned reinforcement and the expression of amphetamine-conditioned reward

Behavioural pharmacology, 2011-04, Vol.22 (2), p.173-181

2011

Volltextzugriff (PDF)

The orexin-1 receptor antagonist SB-334867 reduces amphetamine-evoked dopamine outflow in the shell of the nucleus accumbens and decreases the expression of amphetamine sensitization

Neurochemistry international, 2010, Vol.56 (1), p.11-15

2010

Volltextzugriff (PDF)

Current perspectives on selective dopamine D 3 receptor antagonists as pharmacotherapeutics for addictions and related disorders

Annals of the New York Academy of Sciences, 2010-02, Vol.1187 (1), p.4-34

2010

Volltextzugriff (PDF)

The selective dopamine D3 receptor antagonist SB-277011A significantly accelerates extinction to environmental cues associated with cocaine-induced place preference in male sprague-dawley rats

Synapse (New York, N.Y.), 2015-10, Vol.69 (10), p.512-514

2015

Volltextzugriff (PDF)

5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex

Synapse (New York, N.Y.), 2004-02, Vol.51 (2), p.158-164

2004

Volltextzugriff (PDF)

Differential Role of the Medial and Lateral Prefrontal Cortices in Fear and Anxiety

Behavioral neuroscience, 2000-12, Vol.114 (6), p.1119-1130

2000

Volltextzugriff (PDF)

Pharmacological modulation of functional connectivity: the correlation structure underlying the phMRI response to d -amphetamine modified by selective dopamine D3 receptor antagonist SB277011A

Magnetic resonance imaging, 2007-07, Vol.25 (6), p.811-820

2007

Volltextzugriff (PDF)

1 – 25 von 224

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(212)
Mit Volltextzugriff
(202)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(126)
Life Sciences & Biomedicine
(125)
Animals
(102)
Male
(97)
Rats
(79)
Humans
(59)
Pharmacology & Pharmacy
(59)
Neurosciences & Neurology
(56)
Biological And Medical Sciences
(54)
Neurosciences
(54)
Dopamine
(42)
Medical Sciences
(42)
Rats, Sprague-Dawley
(32)
Pharmacology. Drug Treatments
(30)
Dose-Response Relationship, Drug
(29)
Receptors, Dopamine D3 - Antagonists & Inhibitors
(29)
Female
(28)
Microdialysis
(25)
Cocaine
(22)
Dopamine Antagonists - Pharmacology
(22)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders

Selective antagonism at dopamine D3 receptors as a target for drug addiction pharmacotherapy: a review of preclinical evidence

The medial prefrontal cortex in the rat: evidence for a dorso-ventral distinction based upon functional and anatomical characteristics

Synthetic opioids have disrupted conventional wisdom for treating opioid overdose

Editorial: Discovery, development and implementation of improved options for treating opioid overdose in the synthetic opioid era

Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder

History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder

The introduction of a novel formulation of buprenorphine into organized health systems

SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models

High-performance liquid chromatography/tandem mass spectrometric assay for the simultaneous measurement of dopamine, norepinephrine, 5-hydroxytryptamine and cocaine in biological samples

Selective dopamine D3 receptor antagonism by SB-277011A attenuates cocaine reinforcement as assessed by progressive-ratio and variable-cost-variable-payoff fixed-ratio cocaine self-administration in rats

Antagonism at metabotropic glutamate 5 receptors inhibits nicotine- and cocaine-taking behaviours and prevents nicotine-triggered relapse to nicotine-seeking

The effects of lamotrigine on alcohol seeking and relapse

Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex

Selective antagonism at dopamine D3 receptors attenuates cocaine-seeking behaviour in the rat

Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior

The selective dopamine D3 receptor antagonist SB-277011A attenuates drug- or food-deprivation reactivation of expression of conditioned place preference for cocaine in male sprague-dawley rats

Rationale in support of the use of selective dopamine D3 receptor antagonists for the pharmacotherapeutic management of substance use disorders

Orexin-1 receptor antagonist SB-334867 reduces the acquisition and expression of cocaine-conditioned reinforcement and the expression of amphetamine-conditioned reward

The orexin-1 receptor antagonist SB-334867 reduces amphetamine-evoked dopamine outflow in the shell of the nucleus accumbens and decreases the expression of amphetamine sensitization

Current perspectives on selective dopamine D 3 receptor antagonists as pharmacotherapeutics for addictions and related disorders

The selective dopamine D3 receptor antagonist SB-277011A significantly accelerates extinction to environmental cues associated with cocaine-induced place preference in male sprague-dawley rats

5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex

Differential Role of the Medial and Lateral Prefrontal Cortices in Fear and Anxiety

Pharmacological modulation of functional connectivity: the correlation structure underlying the phMRI response to d -amphetamine modified by selective dopamine D3 receptor antagonist SB277011A

Suchergebnisse filtern